Taletrectinib vs crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)

被引：1

作者：

Nagasaka, M. ^{[1
,2
]}

Liu, G. ^{[3
]}

Pennell, N. ^{[4
]}

Perol, M. ^{[5
]}

Chen, M. ^{[6
]}

Bazhenova, L. ^{[7
]}

Zhou, C. ^{[8
,9
]}

机构：

[1] Univ Calif Irvine, Sch Med, Irvine, CA USA

[2] Chao Family Comprehens Canc Ctr, Orange, CA USA

[3] Univ Toronto, Temerty Sch Med, Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[5] Leon Berard Canc Ctr, Lyon, France

[6] Nuvat Bio, New York, NY USA

[7] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

[8] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Shanghai, Peoples R China

[9] Tongji Univ, Thorac Canc Inst, Sch Med, Shanghai, Peoples R China

来源：

关键词：

D O I：

10.1016/s1556-0864(25)00195-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA2

引用

页码：S1 / S2

页数：2